Biomarkers that can improve risk stratification of patients with prostate cancer are urgently needed. In this Review, Khoo et al. outline mass spectrometry technologies that enable the systematic discovery and targeted validation of protein-based biomarkers in prostate-associated fluids.
- Amanda Khoo
- Lydia Y. Liu
- Thomas Kislinger